TY - JOUR
T1 - Peritoneal carcinomatosis
T2 - A malignant disease with an embryological origin?
AU - Pereira, Augusto
AU - Mendizabal, Elsa
AU - Leon, Juan De
AU - Pérez-Medina, Tirso
AU - Magrina, Javier F.
AU - Magtibay, Paul M.
AU - Rodríguez-Tapia, Ana
AU - Lizarraga, Santiago
AU - Ortiz-Quintana, Luís
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Introduction In 1931, Simpson et al. coined the term "peritoneal carcinomatosis" to describe the regional spread of ovarian tumors as localized or extended with involvement of the peritoneal serous membrane and neighboring anatomical structures. Research into the origin of peritoneal carcinomatosis is based on two phases in a woman's life: Embryo development During week 3, the bilaminar disc becomes a trilaminar disc called the mesoderm. Inside the lateral plate mesoderm, the coelomic cavity is divided into 2 layers: the parietal (somatic) mesoderm, which gives rise to the parietal peritoneum and pleural surfaces; and the visceral (splanchnic) mesoderm, which gives rise to the visceral peritoneum, visceral surface of the pleura, gonadal stroma, and the muscular layer of the hollow viscera and its mesenteries. Tumor spread Transcoelomic metastasis and metaplasia of pluripotent stem cells in the peritoneum was involved in the pathogenesis of ovarian cancer. This involvement takes the form of a synchronous malignant transformation at multiple foci and may cause intraperitoneal field cancerization. Pluripotent stem cells play a role both in the development of the embryonic peritoneum and in the spread of transcoelomic tumors. Consequently, knowledge of the origin of these cells (embryonic or current) could be extremely useful. The many markers that act during the embryonic period can affect descendants, that is, cells are already marked before specification and differentiation are activated. Thus, programmed activation could be attributed to genetic and epigenetic changes.
AB - Introduction In 1931, Simpson et al. coined the term "peritoneal carcinomatosis" to describe the regional spread of ovarian tumors as localized or extended with involvement of the peritoneal serous membrane and neighboring anatomical structures. Research into the origin of peritoneal carcinomatosis is based on two phases in a woman's life: Embryo development During week 3, the bilaminar disc becomes a trilaminar disc called the mesoderm. Inside the lateral plate mesoderm, the coelomic cavity is divided into 2 layers: the parietal (somatic) mesoderm, which gives rise to the parietal peritoneum and pleural surfaces; and the visceral (splanchnic) mesoderm, which gives rise to the visceral peritoneum, visceral surface of the pleura, gonadal stroma, and the muscular layer of the hollow viscera and its mesenteries. Tumor spread Transcoelomic metastasis and metaplasia of pluripotent stem cells in the peritoneum was involved in the pathogenesis of ovarian cancer. This involvement takes the form of a synchronous malignant transformation at multiple foci and may cause intraperitoneal field cancerization. Pluripotent stem cells play a role both in the development of the embryonic peritoneum and in the spread of transcoelomic tumors. Consequently, knowledge of the origin of these cells (embryonic or current) could be extremely useful. The many markers that act during the embryonic period can affect descendants, that is, cells are already marked before specification and differentiation are activated. Thus, programmed activation could be attributed to genetic and epigenetic changes.
KW - Cancer stem cells
KW - Dormant cells
KW - Genetic and epigenetic changes
KW - Lateral plate mesoderm
KW - Ovarian cancer
KW - Peritoneal carcinomatosis
UR - http://www.scopus.com/inward/record.url?scp=84942195514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942195514&partnerID=8YFLogxK
U2 - 10.1016/j.suronc.2015.06.002
DO - 10.1016/j.suronc.2015.06.002
M3 - Article
C2 - 26141556
AN - SCOPUS:84942195514
SN - 0960-7404
VL - 24
SP - 305
EP - 311
JO - Surgical Oncology
JF - Surgical Oncology
IS - 3
ER -